Literature DB >> 11447750

Hepatosplenic gamma/delta T-cell lymphoma in immunocompromised patients. Report of two cases and review of literature.

W A Khan1, L Yu, A B Eisenbrey, D Crisan, A al Saadi, B H Davis, R C Hankin, J C Mattson.   

Abstract

We describe 2 male patients in whom hepatosplenic gamma/delta T-cell lymphoma (HSTL) developed 6 and 10 years after renal transplantation. The onset was abrupt with systemic symptoms, cytopenia, and hepatosplenomegaly. The histologic examination of the spleen (case 1), liver, and bone marrow revealed sinusoidal infiltrates of markedly abnormal lymphocytes. The neoplastic cells in these cases were CD2+, CD3+, CD4-, CD5-, CD7+, CD8+, CD16+, CD56+, beta F1-negative, and TIA-1-negative. Both cases displayed clonal rearrangement of the T-cell receptor (TCR) delta gene and the TCR beta gene. The spleen in case 1 was positive for Epstein-Barr virus genome and showed TCR-gamma gene rearrangement by polymerase chain reaction. Isochromosome 7 [i(7)(q10)] was found in each case. Both patients died within 4 months of diagnosis. HSTL has been reported in only 5 renal transplant recipients. HSTL may be relatively more frequent in immunocompromised patients compared with the general population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11447750     DOI: 10.1309/TC9U-FAV7-0QBW-6DFC

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  13 in total

Review 1.  Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data.

Authors:  Meenakshi Bewtra; F Reed Johnson
Journal:  Patient       Date:  2013       Impact factor: 3.883

Review 2.  Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.

Authors:  Meenakshi Bewtra; James D Lewis
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

3.  Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.

Authors:  Mariko Yabe; L Jeffrey Medeiros; Yahya Daneshbod; Masoud Davanlou; Carlos E Bueso-Ramos; Elisa J Moran; Ken H Young; Roberto N Miranda
Journal:  Ann Diagn Pathol       Date:  2016-10-18       Impact factor: 2.090

4.  Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

Authors:  G S Falchook; F Vega; N H Dang; F Samaniego; M A Rodriguez; R E Champlin; C Hosing; S Verstovsek; B Pro
Journal:  Ann Oncol       Date:  2009-02-23       Impact factor: 32.976

Review 5.  Gamma-delta T-cell lymphomas.

Authors:  Claudio Tripodo; Emilio Iannitto; Ada Maria Florena; Carlo Ennio Pucillo; Pier Paolo Piccaluga; Vito Franco; Stefano Aldo Pileri
Journal:  Nat Rev Clin Oncol       Date:  2009-11-10       Impact factor: 66.675

6.  Hepatosplenic T cell lymphoma with no expression of cytotoxic molecules.

Authors:  Y Sadahira; K Notohara; T Manabe
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

7.  Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience.

Authors:  Martin H Voss; Matthew A Lunning; Jocelyn C Maragulia; Esperanza B Papadopoulos; Jenna Goldberg; Andrew D Zelenetz; Steven M Horwitz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-10-27

8.  Hepatosplenic alpha/beta T-cell lymphoma masquerading as cirrhosis.

Authors:  Jonah Cohen; Eduardo Hariton; Darshan Kothari; German A Pihan; Simon C Robson
Journal:  J Gastrointest Oncol       Date:  2013-06

9.  Pituitary gland involvement by a gamma delta hepatosplenic lymphoma, a mimicker of pituitary adenoma: report of a rare case.

Authors:  D Jain; M C Sharma; C Sarkar; V Suri; A Garg; A K Mahapatra; L Kumar
Journal:  J Neurooncol       Date:  2008-06       Impact factor: 4.130

Review 10.  Biology and management of rare primary extranodal T-cell lymphomas.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Oncology (Williston Park)       Date:  2010-01       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.